| ACS | Acute coronary syndrome |
| RAGE | Advanced glycation end products |
| ATTRwt | Aggregated wild type TTR |
| AD | Alzheimer’s disease |
| Aβ | Amyloid β |
| APP | Amyloid β precursor protein |
| ApoA1 | Apolipoprotein A1 |
| ATTR CA | ATTR cardiac amyloidosis |
| CAVD | Calcific aortic valve disease |
| CNPs | Calcifying nanoparticles |
| CA | Cardiac amyloidosis |
| CVD | Cardiovascular disease |
| CSF | Cerebrospinal fluid |
| CAD | Coronary artery disease |
| DR | Diabetic retinopathy |
| ECM | Extracellular matrix |
| FAP | Familial amyloidotic polyneuropathy |
| HF | Heart failure |
| HFpEF | Heart failure with preserved ejection fraction |
| HDL | High density lipoprotein |
| HMW | High molecular weight |
| HCy | Homocysteine |
| hRECs | Human retinal endothelial cells |
| AL | Immunoglobulin light chain amyloid |
| JIA | Juvenile idiopathic arthritis |
| lncRNA | Long noncoding RNA |
| MMP | Matrix metalloproteinases |
| TFAM | Mitochondrial transcription factor A |
| MMD | Moya-moya disease |
| MPO | Myeloperoxidase |
| NPY | Neuropeptide Y |
| OA | Osteoarthritis |
| PILP | Polymer-induced liquid phase |
| ROS | Reactive oxygen species |
| RA | Rheumatoid arthritis |
| RBP | Retinol-binding protein |
| SSA | Senile systemic amyloidosis |
| SAA | Serum amyloid A |
| TUDCA | Tauroursodeoxycholic acid |
| tPA | Tissue-type plasminogen activator |
| T2DM | Type 2 diabetes mellitus |
| UPR | Unfolded protein response |
| PAM | Peptidylglycine α-amidating monooxygenase |
| VC | Vascular calcification |
| VSMCs | Vascular smooth muscle cells |